TP53 and acute myeloid leukemia: The p53-reactivating compound APG-115 demonstrated synergy with immune checkpoint blockade [71], local activation of p53 in the TME enhances antitumor immunity through ICD and p53-dependent elimination of immunosuppressive MDSCs [72], and NK cells were shown to be crucial for efficacy of the p53-activating drug DS-5272 in AML [73].